Correlation Between Chemotherapy-Induced Nausea and Vomiting with Quality of Life in Patients with Ovarian Cancer at Dr. Cipto Mangunkusumo Hospital.
| Autor: | Madjid, Veinardi, Calvin, David, Purwoto, Gatot, Utami, Tofan Widya, Anggraeni, Tricia Dewi, Vidiawati, Dhanasari, Winarto, Hariyono |
|---|---|
| Předmět: |
CROSS-sectional method
PATIENT compliance PEARSON correlation (Statistics) CRONBACH'S alpha OVARIAN tumors QUESTIONNAIRES RESEARCH methodology evaluation RESEARCH evaluation MULTIPLE regression analysis HOSPITALS CANCER patients CARBOPLATIN DESCRIPTIVE statistics MULTIVARIATE analysis CANCER chemotherapy QUALITY of life STATISTICS VOMITING PACLITAXEL DRUGS DATA analysis software NAUSEA REGRESSION analysis EVALUATION DISEASE complications |
| Zdroj: | Makara Journal of Health Research; Aug2024, Vol. 28 Issue 2, p97-105, 9p |
| Abstrakt: | Introduction: Nausea and vomiting (NV) remain as side effects of chemotherapy, which has a detrimental effect on patients' quality of life (QOL) and treatment adherence. This study aimed to determine the effect of chemotherapy-induced NV (CINV) on the QOL of patients with ovarian cancer treated with chemotherapy at Dr. Cipto Mangunkusumo Hospital (CMH). Methods: We conducted a cross-sectional study in patients with ovarian cancer receiving first-line chemotherapy regimens of carboplatin and paclitaxel. The European Organisation for Research and Treatment helped translate the Quality-of-Life Questionnaire-OV28 (QLQ-OV28) into Indonesian and tested it in a preliminary study. The approved Indonesian version of the QLQ-OV28, with the Quality-of-Life Questionnaire-C30 (QLQ-C30), was then used to evaluate QOL before and 1 week after chemotherapy. Results: Several symptom scales increased, whereas function scales decreased. Moreover, 72.5% had an increase in the NV symptom scale, whereas 67.5% had a decrease in patients' scale after chemotherapy. CINV had a significant partial effect on reducing QOL (p = 0.047 and y = 12.208-0.432). Conclusions: CINV has a significant influence on lowering the QOL of patients with ovarian cancer undergoing first-line chemotherapy regimens with carboplatin and paclitaxel in CMH. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|